What a surprise. The big banks are not playing by the rules -- the rule of law, that is.
News last week revealed that Bank of America Corp. (NYSE:BAC) and JPMorgan Chase & Co. (NYSE:JPM) are dirty, dirty, dirty.
The Justice Department announced that it is pursuing a civil lawsuit against Bank of America on the grounds that the bank lied about the quality of the mortgages underlying its mortgage-backed securities (MBS) prior to the housing collapse and financial crisis. The Justice Department is still on a high from its successful civil lawsuit against Goldman Sachs Group Inc.'s (NYSE:GS) mid-level toxic securities shill, Fabrice Tourre.
The charges allege out-and-out fraud in Bank of America's soup-to-nuts loan origination and securitization of mortgages. Loans, bad from the start, were knowingly bundled and securitized into trade-able MBS, unbeknownst to buyers.
As we all know, this play went wrong (or worked spectacularly well, if you were short housing like John Paulson) and spread poison throughout the global financial system. It is alleged that this particular fraud led to losses of at least $100 million among investors who thought they were buying securities backed by mortgages that weren't worthless.
Top Chemical Stocks To Invest In Right Now: Aceto Corporation(ACET)
Aceto Corporation engages in the sourcing, regulatory support, marketing, and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals worldwide. The company operates in three segments: Health Sciences, Specialty Chemicals, and Agricultural Protection Products. The Health Sciences segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. The Specialty Chemicals segment provides various chemicals used in plastics, surface coatings, textiles, fuels, and lubricants; organic intermediates used in the production of agrochemicals; and dye and pigment intermediates used in the color-producing industries, such as textiles, inks, paper, and coatings. This segment also offers diazos and couplers to the paper, film, and electronics industries. The Agricultural Protection Products segment sells herbicides, fungicides, insecticides, and other agricultural chemicals that control weed growth, as well as control the spread of insects and other microorganisms that can damage plant growth. This segment also provides sprout inhibitor for potatoes and an herbicide for sugar cane. It serves pharmaceutical, nutraceutical, agricultural, coatings, and industrial chemical consuming industries. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.
Advisors' Opinion:- [By Monica Gerson]
Aceto (NASDAQ: ACET) is projected to post its Q4 earnings at $0.17 per share on revenue of $134.23 million.
SeaChange International (NASDAQ: SEAC) is estimated to post a Q2 loss at $0.18 per share on revenue of $26.80 million.
5 Best Quality Stocks To Own For 2015: Broadwind Energy Inc.(BWEN)
Broadwind Energy, Inc. provides products and services to the energy, mining, and infrastructure sector customers, primarily in the United States. The company?s Towers and Weldments segment manufactures towers designed for two megawatt and larger wind turbines. This segment also manufactures specialty fabrications and weldments for mining and other industrial customers. Its Gearing segment engineers, builds, and remanufactures precision gears and gearing systems for wind, oil and gas, mining, and other industrial applications. The company?s Services segment offers a range of services, including non-routine blade and gearbox maintenance services for both kilowatt and megawatt turbines primarily to wind farm developers and operators. It also provides field services to the wind industry; dedicated drivetrain services; and industrial gearboxes precision repair and testing services. The company provides its products and services to various wind energy customers that include wi nd turbine manufacturers, wind farm developers, and wind farm operators, as well as oil and gas, mining, and other industries. It sells its products through its sales force and manufacturers' representatives. The company was formerly known as Tower Tech Holdings Inc. and changed its name to Broadwind Energy, Inc. in 2008. Broadwind Energy, Inc. is headquartered in Naperville, Illinois.
Advisors' Opinion:- [By Monica Gerson]
Broadwind Energy (NASDAQ: BWEN) is projected to post a Q4 loss at $0.19 per share on revenue of $56.54 million.
Orexigen Therapeutics (NASDAQ: OREX) is estimated to post a Q4 loss at $0.19 per share on revenue of $900.00 thousand.
- [By John Udovich]
Small cap wind stock Broadwind Energy Inc (NASDAQ: BWEN) is up 203.7% since the start of the year, but investors might want to contain their excitement when they look closer at the�stock and�consider its�long term performance along with the performance of other wind investments like First Trust Global Wind Energy ETF (NYSEARCA: FAN) and wind energy stocks Vestas Wind Systems (OTCMKTS: VWDRY) and China Ming Yang Wind Power Group Ltd (NYSE: MY) to see whether BWEN is just blowing more hot air.
- [By John Udovich]
Small cap Ocean Power Technologies Inc (NASDAQ: OPTT) just sank 34% on news that they have fired their CEO "for cause,��meaning its worth taking a closer look at the stock to see if there is anything to salvage (shares were rising more than 6% in after hours) plus take a look at the performance of potential renewable energy related peers like Ormat Technologies, Inc (NYSE: ORA), Broadwind Energy Inc (NASDAQ: BWEN) and China Ming Yang Wind Power Group Ltd (NYSE: MY).
5 Best Quality Stocks To Own For 2015: Juno Therapeutics Inc (JUNO)
Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.
To provide treatment, the Company harvests blood cells from a cancer patient, separate the appropriate T cells, activate the cells, insert the gene sequence for the CAR or TCR construct into the cells��Deoxyribonucleic Acid (DNA), and grow these modified T cells to the desired dose level. The modified T cells can then be infused into the patient or frozen and stored for later infusion. Once infused, the T cells are designed to multiply, through a process known as cell expansion, when they encounter the targeted proteins and to kill the targeted cancer cells.
CD19-Directed Product Candidates
The Company�� product candidates, such as JCAR015, JCAR017, and JCAR014, which use CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. The Company has rights to commercialize each of these product candidates across the world. The Company�� JCAR015 is an advanced development product candidate, and it has demonstrated clinically meaningful complete remission rates in adult patients with r/r ALL. JCAR015 uses the CD28 costimulatory domain and CD3 enriched peripheral blood mononuclear cells (PBMC), which requires fewer process steps for! manufacture than its defined cell composition product candidates. JCAR015 is being tested in a Phase I open label clinical trial of patients with r/r ALL for the treatment of refractory chronic lymphocytic leukemia.
JCAR017 also targets CD19, but differs from JCAR015 in several important respects. JCAR017 uses the 4-1BB costimulatory domain and a defined cell composition of CD4+ T cells and CD8+ T cells. JCAR017 is in development for pediatric patients with r/r ALL. JCAR017 is being evaluated in a Phase I/II clinical trial in pediatric r/r ALL.
JCAR014 also targets CD19. JCAR014 uses the 4-1BB costimulatory domain and is composed of CD8+ central memory T cells and CD4+ T cells in a defined ratio. JCAR014 is being evaluated in a Phase I/II trial as a treatment for a number of B cell malignancies in patients relapsed or refractory to standard therapies.
Additional Product Candidates
The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers not targeted by CD19-directed products, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung, and pancreatic cancers, as well as B cell malignancies that do not express CD19. The Company�� CD22 is a cell surface protein widely expressed on B lymphocytes. It is expressed by B cell malignancies, including non-Hodgkin�� lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The Company�� L1CAM, also known as CD171, is a cell-surface adhesion molecule that plays an important role in the development of a normal nervous system. It is overexpressed in neuroblastoma, and there is increasing evidence of aberrant expression in a variety of solid organ tumors, including glioblastoma and lung, pancreatic, and ovarian cancers.
The Company�� MUC-16 is a protein overexpressed in the ovarian cancers, but not on the surface of normal ovary cells. CA-125 is a protein found in the ! blood of ! ovarian cancer patients that results from the cleavage of MUC-16. CA-125 levels in the blood are a common test for ovarian cancer progression because they correlate with cancer progression. Its MUC-16/IL-12 product candidate uses its armored CAR technology. IL-12 is a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity.
The Company�� ROR-1 is a protein expressed in the formation of embryos, but in normal adult cells its surface expression is predominantly found at low levels on adipocytes, or fat cells, and briefly on precursors to B cells, or pre-B cells, during normal B cell maturation. ROR-1 is overexpressed on a variety of cancers including a subset of non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, and prostate cancer. It is expressed on B cell chronic lymphocytic leukemia and mantle cell lymphoma. The Company�� high-affinity TCR T cell product candidate targets WT-1, an intracellular protein that is overexpressed in a number of cancers, including adult myeloid leukemia, or AML, and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.
Advisors' Opinion:- [By John Udovich]
Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.
5 Best Quality Stocks To Own For 2015: Compania Mina Buenaventura S.A. (BVN)
Compania de Minas Buenaventura S.A.A., a precious metals company, engages in the exploration, mining, processing, and development of gold, silver, and other metals in Peru. It also explores for zinc, lead, and copper. The company operates the Orcopampa mine located in the province of Castilla in the department of Arequipa; the Uchucchacua mine located in the province of Oyon in the department of Lima; the La Zanja mine located in the district of Pulan in the province of Santa Cruz; the Antapite mine located in the province of Huaytara in the department of Huancavelica; the Julcani mine located in the province of Angaraes in the department of Huancavelica; and the Recuperada mine located in the province of Huancavelica in the department of Huancavelica. It also holds controlling interests in the Colquijirca and Marcapunta Norte mines located east of the city of Lima; and the Shila-Paula mines located in the province of Castilla in the department of Arequipa. In addition, th e company owns interests in various other mining companies. Further, it offers electric power transmission services; and geological, engineering, design, and construction consulting services to the mining sector. Compania de Minas Buenaventura S.A.A. was founded in 1953 and is headquartered in Lima, Peru.
Advisors' Opinion:- [By Johanna Bennett]
Analyst John Bridges and his team like Goldcorp (GG), B2Gold (BTG) and Eldorado (EGO), and feel Buenaventura (BVN) is a serious laggard with likely improved results in the second half of 2014. They write:
- [By Seth Jayson]
Compa帽铆a de Minas Buenaventura S.A.A. (NYSE: BVN ) is expected to report Q2 earnings around July 26. Here's what Wall Street wants to see:
- [By Anthony Mirhaydari]
Amid the chaos, safe haven assets like gold (GLD) are perking up in a big way — bringing buyers back into a sector that I think will continue to be a big performer throughout 2014. Here are three gold stocks to buy that are currently on the move:
Breakout Gold Stocks to Buy: Compania de Minas Buenaventura (BVN)Compania de Minas Buenaventura (BVN) is a Peruvian gold and silver miner with operations throughout the country. Its output makes it the world’s third-largest producer of silver.
No comments:
Post a Comment